Tag - LIXT

LIXTE Biotechnology (NASDAQ:LIXT) has announced that, in collaboration with the Netherlands Cancer Institute (NKI), the first patient has been dosed in a new clinical trial of LUXTE’s lead compound, LB-100, for the...